HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC
Future Oncology · 01.06.2023 · 19 (19) · 1319-1329
DOI: 10.2217/fon-2022-1250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, online erschienen am 22.05.2023. Verfasst von Helena A Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo.
Abstract (Originalsprache)
Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC. Clinical Trial Registration: NCT04619004 (ClinicalTrials.gov); 2020-000730-17 (EudraCT). This article describes a clinical trial of a new drug to treat non-small-cell lung cancer. About a third of patients with non-small-cell lung cancer have tumors with changes (mutations) in a gene called EGFR, which cause tumors to grow. These patients are treated with EGFR inhibitors and chemotherapy, both of which can stop the tumor from growing for a period of time. When these treatments stop working, new and effective treatments are needed. Most non-small-cell lung cancer tumors have a protein called HER3 on the surface of their cells. Patritumab deruxtecan (HER3-DXd) is a new drug candidate that uses HER3 to get chemotherapy inside tumor cells. In an earlier clinical trial for patients with lung cancer whose disease had grown after multiple treatments, HER3-DXd often shrank tumors or stopped them from growing. The side effects of HER3-DXd were tolerable. The clinical trial described in this publication, HERTHENA-Lung01 (NCT04619004), is testing HER3-DXd in a larger group of patients with non-small-cell lung cancer that has activating mutations in the EGFR gene and for whom previous treatments have stopped working. The results of this study will help doctors and regulators decide if HER3-DXd should be approved and used for patients with non-small-cell lung cancer with EGFR mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Oncology, National Taiwan University Hospital, Taipei City, 100, Taiwan.
- Department of Medical Oncology, Kindai University, Osaka, 589-8511, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
- Medical Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, 08035, Barcelona, Spain.
- Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, 22927, Grosshansdorf, Germany.
ORCID-Profile: James Chih-Hsin Yang, Hidetoshi Hayashi, Yasushi Goto, Martin Reck, Pang-Dian Fan, Pasi A Jänne
Förderung
- Daiichi-Sankyo
Zitieren
APA
Yu, H. A., Yang, J. C., Hayashi, H., Goto, Y., Felip, E., Reck, M., Vigliotti, M., Dong, Q., Cantero, F., Fan, P. D., Kanai, M., Sternberg, D. W., & Jänne, P. A. (2023). HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC. Future Oncology, 19(19), 1319-1329. https://doi.org/10.2217/fon-2022-1250
Vancouver
Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, et al. HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC. Future Oncology. 2023;19(19):1319-1329. doi:10.2217/fon-2022-1250
BibTeX
@article{Yu2023,
author = {Yu, Helena A and Yang, James Chih-Hsin and Hayashi, Hidetoshi and Goto, Yasushi and Felip, Enriqueta and Reck, Martin and Vigliotti, Michele and Dong, Qian and Cantero, Frédérique and Fan, Pang-Dian and Kanai, Masayuki and Sternberg, David W and Jänne, Pasi A},
title = {HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {19},
pages = {1319--1329},
doi = {10.2217/fon-2022-1250}
}
EUVIMED